دورية أكاديمية
Cyclin-Dependent Kinase 4/6 Inhibitors Against Breast Cancer.
| العنوان: | Cyclin-Dependent Kinase 4/6 Inhibitors Against Breast Cancer. |
|---|---|
| المؤلفون: | Hassan MA; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Ankara University, Ankara, Turkey., Ates-Alagoz Z; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Ankara University, Ankara, Turkey. |
| المصدر: | Mini reviews in medicinal chemistry [Mini Rev Med Chem] 2023; Vol. 23 (4), pp. 412-428. |
| نوع المنشور: | Review; Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Bentham Science Publishers Country of Publication: Netherlands NLM ID: 101094212 Publication Model: Print Cited Medium: Internet ISSN: 1875-5607 (Electronic) Linking ISSN: 13895575 NLM ISO Abbreviation: Mini Rev Med Chem Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Hilversum, The Netherlands; Boca Raton, FL : Bentham Science Publishers, c2001- |
| مواضيع طبية MeSH: | Breast Neoplasms*/drug therapy , Breast Neoplasms*/pathology , Antineoplastic Agents*/pharmacology , Antineoplastic Agents*/therapeutic use, Female ; Humans ; Cyclin-Dependent Kinase 4/therapeutic use ; Protein Kinase Inhibitors/pharmacology ; Protein Kinase Inhibitors/therapeutic use |
| مستخلص: | Breast cancer is the most frequently diagnosed and leading cause of cancer-related deaths in women worldwide. Based on global cancer (GLOBOCAN) 2020 statistics, 1 in 4 cancer cases and 1 in 6 cancer deaths are attributable to breast cancer, leading both in incidence and mortality. To address the increasing burden of cancer, novel therapeutic approaches that target key hallmarks of cancer are explored in cancer drug discovery. Cyclin-dependent kinase (CDK) inhibitors are generally purine and pyrimidine analogues validated for the treatment of cancer due to their unique roles in cancer deregulation and novel therapeutic potentials. So far, three orally administered, potent and highly selective CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib) have been approved by the FDA for the targeted treatment of advanced or metastatic breast cancer in combination with endocrine therapy. Furthermore, several compounds derived from various synthetic scaffolds are being explored with promising results and positive outcomes in various stages of clinical trials. In this review, we highlight these CDK4/6 inhibitor compounds with potent anti-CDK4/6, in vitro and in vivo activities on breast cancer cells. With the remarkable prospects of these compounds, there is great optimism further novel CDK inhibitor compounds will be discovered in the future that could boost therapeutic options for cancer treatment. (Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.) |
| فهرسة مساهمة: | Keywords: CDK4/6; Cyclin-dependent kinase inhibitors; breast cancer; cell cycle; cyclin-D; synthetic scaffolds |
| المشرفين على المادة: | EC 2.7.11.22 (Cyclin-Dependent Kinase 4) 0 (Antineoplastic Agents) 0 (Protein Kinase Inhibitors) |
| تواريخ الأحداث: | Date Created: 20220607 Date Completed: 20230316 Latest Revision: 20230316 |
| رمز التحديث: | 20230320 |
| DOI: | 10.2174/1389557522666220606095540 |
| PMID: | 35670349 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1875-5607 |
|---|---|
| DOI: | 10.2174/1389557522666220606095540 |